8-K filing — Aldeyra Therapeutics, Inc. (ALDX)
Filed: 2026-07-30 AccNo: 0001193125-26-326337 Size: 20 MB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Read original at edgarFilings · News reference
Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026
SEC Filing
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 9:04 PM
- Checked
- Jul 15, 2026, 9:04 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading